Platinum(IV)-Estramustine Multiaction Prodrugs Are Effective Antiproliferative Agents against Prostate Cancer Cells
Author:
Affiliation:
1. Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel
2. Institute of Biophysics, Czech Academy of Sciences, Kralovopolska 135, Brno CZ-61265, Czech Republic
Funder
Israel Cancer Association
Israel Science Foundation
Grantov? Agentura Cesk? Republiky
Alex Grass Center for Drug Design and synthesis, Hebrew University of Jerusalem
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01400
Reference85 articles.
1. Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance
2. Dual‐Targeting Dual‐Action Platinum(IV) Platform for Enhanced Anticancer Activity and Reduced Nephrotoxicity
3. Platinum (IV) Derivatives with Cinnamate Axial Ligands as Potent Agents Against Both Differentiated and Tumorigenic Cancer Stem Rhabdomyosarcoma Cells
4. A Photoactivatable Platinum(IV) Complex Targeting Genomic DNA and Histone Deacetylases
5. Cisplatin in cancer therapy: Molecular mechanisms of action
Cited by 36 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advancements in platinum-based anticancer drug development: A comprehensive review of strategies, discoveries, and future perspectives;Bioorganic & Medicinal Chemistry;2024-10
2. Biotin–Pt(IV)–Ru(II)–Boron–Dipyrromethene Prodrug as “Platin Bullet” for Targeted Chemo- and Photodynamic Therapy;Inorganic Chemistry;2024-09-05
3. Multiaction Pt(IV) Complexes: Cytotoxicity in Ovarian Cancer Cell Lines and Mechanistic Studies;Inorganic Chemistry;2024-07-31
4. Multiaction Pt(IV) Prodrugs Releasing Cisplatin and Dasatinib Are Potent Anticancer and Anti-Invasive Agents Displaying Synergism between the Two Drugs;Journal of Medicinal Chemistry;2024-05-31
5. Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated PlatinumIV Complexes as Potent Antitumor Agents;Journal of Medicinal Chemistry;2024-05-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3